Childhood neoplasm
MONDO:0021079A benign or malignant neoplasm arising during childhood.
Also known as: childhood neoplasm, childhood neoplasm (disease), childhood tumor, childhood tumour, neoplasm (disease) of childhood, paediatric neoplasm, paediatric neoplasm (disease), paediatric tumour
1835 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Custom-Made cancer vaccine enters early human testing
⭐️ VACCINE ⭐️ Not yet recruitingThis study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in 50 adults with solid tumors. The goal is to see if the vaccine is safe and triggers an immune response against the cancer. Participants must have good organ function and …
Phase: EARLY_PHASE1 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:33 UTC
-
New drug DS1025a takes on advanced solid tumors in first human trial
Disease control Not yet recruitingThis trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Engineered immune cells target deadly brain tumors in children
Disease control Not yet recruitingThis study tests a new treatment called BCB-276 for children and young adults with diffuse intrinsic pontine glioma (DIPG), a rare and aggressive brain tumor. BCB-276 is made from a patient's own immune cells, which are modified in a lab to recognize and attack the cancer. The tr…
Phase: PHASE2 • Sponsor: BrainChild Bio, Inc • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Bicycle therapies offer continued hope for advanced tumors
Disease control Not yet recruitingThis trial provides continued access to three experimental Bicycle therapies—zelenectide pevedotin, nuzefatide pevedotin, and BT7480—for people with advanced solid tumors who are already benefiting from them in another study. Participants continue their same treatment while resea…
Phase: PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New antibody drug targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…
Phase: PHASE1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered immune cells take on childhood brain cancer in first human trial
Disease control Not yet recruitingThis early-phase study tests a new treatment for children and young adults with aggressive brain tumors called high-grade glioma and DIPG. The therapy uses the patient's own immune cells, modified in a lab to better recognize and attack tumor cells. The main goals are to see if t…
Phase: PHASE1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New cancer drug candidate SHR-4685 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new drug called SHR-4685 in people with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 170 adults aged 18 to 75 with meas…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Radioactive beads take aim at inoperable liver tumors
Disease control Not yet recruitingThis trial tests a treatment called Yttrium-90 radiation segmentectomy for people with liver cancer that can't be removed by surgery. Tiny radioactive beads are injected into the blood supply of the tumor to deliver targeted radiation. The study will enroll 64 participants to see…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug XYA02 takes on tough cancers in first human trial
Disease control Not yet recruitingThis study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…
Phase: PHASE1, PHASE2 • Sponsor: XYone Therapeutics, Inc • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Extended look at gotistobart: could Long-Term use improve survival in advanced cancers?
Disease control Not yet recruitingThis extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …
Phase: PHASE3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Sound waves open brain barrier to deliver cancer drug in kids
Disease control Not yet recruitingThis early-stage trial tests whether using focused ultrasound with microbubbles can temporarily open the blood-brain barrier, allowing the immunotherapy drug nivolumab to reach brain tumors more effectively. It includes 30 children and young adults with relapsed diffuse midline g…
Phase: PHASE1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New bispecific antibody D3L-002 enters first human trial for Hard-to-Treat cancers
Disease control Not yet recruitingThis Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…
Phase: PHASE1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental T-Cell therapy takes on advanced cancers
Disease control Not yet recruitingThis early-stage trial is testing a new cell therapy called GK01 in 10 people with advanced solid tumors that have stopped responding to standard treatments. The therapy uses the patient's own immune cells (T cells) that are trained to attack the tumor. The main goal is to check …
Phase: EARLY_PHASE1 • Sponsor: Beijing Geekgene Technology Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingThis study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.
Phase: PHASE2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could simple Over-the-Counter drugs supercharge cancer immunotherapy?
Disease control Not yet recruitingThis study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…
Phase: PHASE2 • Sponsor: Val Adams • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New cancer drug LNF2105 enters first human trials
Disease control Not yet recruitingThis early-stage trial tests LNF2105, a drug designed to target and deliver a toxin to cancer cells that have a protein called Nectin-4 on their surface. It will enroll about 294 adults with advanced solid tumors (such as bladder, breast, or lung cancer) who have run out of stand…
Phase: PHASE1 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental injection trains immune cells inside the body to fight cancer
Disease control Not yet recruitingThis early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could an antibody boost chemo for tough blood cancers?
Disease control Not yet recruitingThis large clinical trial is testing whether adding the drug daratumumab to standard chemotherapy helps children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL). Daratumumab is an antibody that targets a pr…
Phase: PHASE2, PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug CS5007 targets tough cancers in first human trial
Disease control Not yet recruitingThis early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …
Phase: PHASE1 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…
Phase: PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets tough cancers with KRas G12V mutation
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…
Phase: PHASE1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising drug combo targets aggressive brain cancers in youth
Disease control Not yet recruitingThis study is for adolescents and young adults (ages 12-39) newly diagnosed with aggressive brain tumors called high-grade glioma or DIPG. The goal is to see if a combination of two immunotherapy drugs (relatlimab and nivolumab, sold as Opdualag) is safe and tolerable when given …
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New Antibody-Drug conjugate enters early human trials for advanced cancers
Disease control Not yet recruitingThis Phase 1 trial tests MST-168, an antibody-drug conjugate designed to target and kill cancer cells. It will enroll 420 adults with advanced solid tumors that have specific markers. The main goals are to check safety, find the right dose, and see early signs of tumor shrinkage.
Phase: PHASE1 • Sponsor: Mabsoft Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo aims to wipe out hidden leukemia cells
Disease control Not yet recruitingThis study tests whether adding a new drug called revumenib to the usual treatment (blinatumomab plus chemotherapy) can better clear leftover leukemia cells in people with a specific genetic type of B-cell acute lymphoblastic leukemia (ALL) or mixed-lineage leukemia. About 90 adu…
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New injection YKYY031 enters human testing for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …
Phase: PHASE1 • Sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug targets hard-to-treat cancers in early trial
Disease control Not yet recruitingThis study tests a drug called Trastuzumab Rezetecan in 15 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug can shrink tumors. Participants get the drug by IV every 3 weeks. This is for people whose cancer has worsened after other treat…
Phase: PHASE2 • Sponsor: Haihua Yuan • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for kids with resistant cancers: targeted drug enters trial
Disease control Not yet recruitingThis study tests a drug called ifinatamab deruxtecan (I-DXd) in children with solid tumors that have returned or not responded to treatment. The drug is an antibody-drug conjugate that targets cancer cells directly. The trial aims to check safety and see if tumors shrink in about…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill takes on advanced cancers in first human test
Disease control Not yet recruitingThis early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…
Phase: PHASE1 • Sponsor: Groovy Medicine (Hangzhou) Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New antibody drug aims to outsmart tumors by targeting two immune pathways
Disease control Not yet recruitingThis study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have …
Phase: PHASE1, PHASE2 • Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New pill targets hard-to-treat cancers with KRAS G12D mutation
Disease control Not yet recruitingThis early-stage study tests a new tablet, LT-010391, in people with advanced solid tumors (lung, colon, or pancreatic cancer) that have a specific genetic change called KRAS G12D. The main goals are to check safety and find the right dose. About 198 participants who have tried o…
Phase: PHASE1 • Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for kids with aggressive brain cancer: hormone therapy plus chemo
Disease control Not yet recruitingThis study tests a thyroid hormone called liothyronine (L-T3) alone or with standard chemotherapy in children and young adults whose medulloblastoma has come back or worsened. The goal is to see if adding L-T3 can help control the cancer better. About 69 participants will take pa…
Phase: PHASE1, PHASE2 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for advanced cancer patients as experimental drug enters trials
Disease control Not yet recruitingThis study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…
Phase: PHASE1, PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug (SYS6006) combined with another drug (Enlonstobart) in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and works better than Enlonstobart alone. About 264 adults will tak…
Phase: PHASE1, PHASE2 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug QLC5508 enters first human safety tests
Disease control Not yet recruitingThis early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune cell therapy takes on advanced cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new treatment called CAR-DC for people with advanced solid tumors (like lung, liver, or stomach cancer) that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells. …
Phase: EARLY_PHASE1 • Sponsor: Peking University Shenzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug Hemay5087 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new drug called Hemay5087 in 24 people with advanced solid tumors that have not responded to standard treatments or have no standard options. The main goals are to check safety, find the right dose, and get a first look at whether the drug can shrin…
Phase: PHASE1 • Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New cancer drug HH160 enters first human tests for advanced tumors
Disease control Not yet recruitingThis early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for Hard-to-Treat cancers: drug targets MTAP deletion
Disease control Not yet recruitingThis phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New injection targets cancer fluid in lungs and belly
Disease control Not yet recruitingThis early-phase trial tests a new drug called WSK-IM02 in 9 people with advanced solid tumors that have spread to cause fluid buildup around the lungs or in the belly. The drug is given directly into the chest or abdomen to see if it is safe and can shrink tumors or reduce fluid…
Phase: PHASE1 • Sponsor: WestVac Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo drug trial hopes to shrink Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a combination of two drugs, CVL006 and 9MW2821, in 108 adults with advanced solid tumors that have not responded to standard therapy. The goal is to find a safe dose and see if the combination can shrink tumors. The study is not yet recruiting.
Phase: PHASE1, PHASE2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug CS231295 enters first human trial for tough cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called CS231295 in 42 adults with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking certain proteins that help tumors grow and form blood vessels. The main goals are to check safety, find …
Phase: PHASE1 • Sponsor: ThalassaX Therapeutics United States Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new drug, BI 1831169, combined with an existing immunotherapy (nivolumab) in Japanese adults with advanced solid tumors that have spread or not responded to prior treatments. The main goal is to find a safe, tolerable dose. Up to 46 participants wil…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New injection shows promise for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug IDP-001 takes on advanced cancers in early trial
Disease control Not yet recruitingThis study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…
Phase: PHASE1, PHASE2 • Sponsor: InduPro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New liposome drug takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called HF50 in 45 adults with advanced solid tumors that have not responded to standard treatments. HF50 is designed to target HER2 on cancer cells and boost the immune system. The main goals are to check safety, find the right dose, and se…
Phase: PHASE1 • Sponsor: HighField Biopharmaceuticals Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug IN10028 tested for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called IN10028 in 75 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors when used alone or with other cancer drugs. Th…
Phase: PHASE1 • Sponsor: InxMed (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug 'Unmasks' cancer cells to immune system in early trial
Disease control Not yet recruitingThis early-stage trial tests a new drug (non-cationic peptide-CD47 siRNA) in about 9 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a 'don't eat me' signal on cancer cells, helping the immune system recognize and attack t…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New Dual-Targeting antibody enters human trials for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called JH021 in 60 people with advanced solid tumors that have stopped responding to standard treatments. JH021 is a special antibody that targets two cancer-related proteins, EGFR and cMET, to potentially slow or stop tumor growth. The mai…
Phase: PHASE1 • Sponsor: Biotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug SKB118 aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingThis study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could early antibiotic stop be safe for kids with cancer?
Disease control Not yet recruitingThis trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…
Phase: PHASE4 • Sponsor: Hospital Universitari Vall d'Hebron Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug SYS6051 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase trial tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants receive the drug by IV every three weeks.
Phase: PHASE1 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug SKB565 aims to fight advanced solid tumors
Disease control Not yet recruitingThis study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…
Phase: PHASE1, PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New Shot-in-the-Skin cancer drug tested in Real-World patients
Disease control Not yet recruitingThis study looks at envafolimab, a cancer drug given as a quick shot under the skin instead of a long IV drip. It is for adults with advanced solid tumors who have not responded to standard treatments. The goal is to see how well it controls tumors and what side effects occur in …
Sponsor: IR INNOVATE RESEARCH PRIVATE LIMITED • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Sound waves could open Brain's barrier to fight deadly tumor
Disease control Not yet recruitingThis study tests a new way to treat a rare and aggressive brain tumor called diffuse midline glioma (DMG) in the brainstem. The approach uses MRI-guided focused ultrasound to temporarily open the blood-brain barrier, allowing more of the chemotherapy drug temozolomide to reach th…
Phase: PHASE1, PHASE2 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug FXB0871 takes on advanced cancers in first human trial
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called FXB0871 in about 138 adults with advanced solid tumors, including non-small cell lung cancer and liver cancer, that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and se…
Phase: PHASE1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New study aims to help childhood leukemia survivors fight weight gain
Disease control Not yet recruitingThis study compares two weight management programs for children who have had acute lymphoblastic leukemia (ALL). About 80 children and their caregivers will be randomly assigned to either a basic educational program or a more intensive guided self-help program. The goal is to see…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Can engineered red blood cells fight cancer? new trial launches
Disease control Not yet recruitingThis early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…
Phase: EARLY_PHASE1 • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug KIVU-305 takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find a safe dose and see if the…
Phase: PHASE1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New CAR-T therapy aims to outsmart resistant blood cancers
Disease control Not yet recruitingThis early study tests a new type of immune cell therapy called Sup19 CAR-T in 9 adults with B-cell acute lymphoblastic leukemia or lymphoma. It is for patients whose cancer stopped responding to previous CD19-targeted treatments or has low levels of CD19. The main goal is to che…
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Snake venom protein tested as cancer treatment in humans
Disease control Not yet recruitingThis early-stage trial tests crotoxin, a protein from rattlesnake venom, given intravenously to 24 adults with advanced solid tumors that have not responded to standard therapy. The main goal is to see if a slow dose increase can make the drug safer and better tolerated. Research…
Phase: PHASE1 • Sponsor: Celtic Biotech Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for advanced cancer: ALK-N001 enters human trials
Disease control Not yet recruitingThis study tests a new drug called ALK-N001 in 190 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every 2 or 3 weeks. Researchers will check if it shrinks tumors, how safe it is, and how the body processes it. The goal is…
Phase: PHASE1, PHASE2 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for advanced cancer patients? early trial of ZE94-0605 begins
Disease control Not yet recruitingThis early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.
Phase: PHASE1 • Sponsor: Eilean Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for kids with deadly brain cancer: targeted drug trial launches
Disease control Not yet recruitingThis study tests a drug called tovorafenib in children and young adults (ages 1 to 39) newly diagnosed with aggressive brain tumors (high-grade glioma or DIPG) that have specific genetic changes. The goal is to see if the drug can help them live longer. About 79 participants will…
Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Ready-Made immune cells take on blood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new cell therapy called ALA-101 for people with CD19+ non-Hodgkin lymphoma or leukemia. The therapy uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to check safety and find the best dose, with …
Phase: PHASE1 • Sponsor: Arovella Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New cell therapy aims to supercharge Kids' immune cells after transplant
Disease control Not yet recruitingThis early-phase trial tests a new cell therapy called ThINKK in 12 children aged 2–12 who have had a stem cell transplant for leukemia or neuroblastoma. The therapy is designed to boost the body's natural killer (NK) cells to better fight cancer. The main goals are to check if t…
Phase: PHASE1 • Sponsor: Michel Duval • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New cancer drug targets HER3 in advanced tumors
Disease control Not yet recruitingThis study tests a new drug called KHN922 in people with advanced solid tumors that have not responded to standard treatments. KHN922 is an antibody-drug conjugate designed to target HER3 proteins on cancer cells and deliver two anti-cancer drugs directly to them. The trial will …
Phase: PHASE1, PHASE2 • Sponsor: Chengdu Kanghong Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New taxane drug RP-001 enters human trials for Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial is testing a new chemotherapy drug called RP-001 in 66 adults with advanced solid tumors, including colorectal and pancreatic cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. It is an open-label study, …
Phase: PHASE1, PHASE2 • Sponsor: Recurv Pharma Inc • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New combo therapy aims to shrink advanced liver and kidney tumors
Disease control Not yet recruitingThis study tests a new drug called WGI-0301 combined with the immunotherapy nivolumab in people with advanced liver or kidney cancer. The goal is to see if the combination is safe and can shrink tumors. About 230 adults aged 18 to 75 will take part, and the study does not use a p…
Phase: PHASE2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug combo aims to shrink Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests an experimental drug called LRK-4189, given alone or with standard chemotherapy, for adults with advanced solid tumors that have not responded to prior treatment. The main goal is to check the drug's safety and find the best dose. About 120 participants will take…
Phase: PHASE1, PHASE2 • Sponsor: LARKSPUR BIOSCIENCES, INC. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a common parasite drug boost cancer immunotherapy?
Disease control Not yet recruitingThis study tests whether adding ivermectin, a drug used for parasitic infections, can improve the immune response in people with solid tumors who are already receiving immunotherapy. About 80 adults will take either a moderate or high dose of ivermectin for four weeks alongside t…
Phase: PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cancer drug SIG001 enters first human tests
Disease control Not yet recruitingThis early-stage trial tests a new biologic drug, SIG001, in 66 people with advanced solid tumors. The main goals are to check safety, find the right dose, and see how the drug behaves in the body. Participants receive SIG001 intravenously every two weeks and are monitored for si…
Phase: PHASE1 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New immune therapy aims to stop relapse in kids with aggressive T-Cell cancer
Disease control Not yet recruitingThis early-phase trial tests a single infusion of CD7 CAR-T cells in 10 children with high-risk T-cell acute lymphoblastic leukemia or lymphoma who have already achieved remission. The goal is to see if this immune cell therapy can safely eliminate remaining cancer cells and redu…
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests an experimental oral drug, BPI-572270, in 120 adults with advanced solid tumors (lung, colorectal, or pancreatic cancer) that have specific RAS gene mutations. The trial has two phases: first to find a safe dose and check for side effects, then to see if the drug…
Phase: PHASE1, PHASE2 • Sponsor: Betta Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug targets stomach and pancreatic cancers in early trial
Disease control Not yet recruitingThis study tests a new drug called LCB02A for people with advanced solid tumors that have a specific marker (CLDN18.2) and haven't responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The trial has two phases: first, finding the safe…
Phase: PHASE1, PHASE2 • Sponsor: LigaChem Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug QLS5308 enters human testing for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called QLS5308 in about 192 adults with advanced solid tumors that have spread and cannot be removed by surgery or radiation. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants m…
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Gene test could make leukemia treatment safer for kids
Disease control Not yet recruitingThis study aims to see if using a child's genetic information to decide the dose of a chemotherapy drug (6-MP) can reduce dangerous side effects like low white blood cell counts and infections. About 110 children with acute lymphoblastic leukemia will receive a personalized dose …
Phase: NA • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo targets advanced cancers in early trial
Disease control Not yet recruitingThis study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…
Phase: PHASE1, PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for deadly brain cancer? early trial launches
Disease control Not yet recruitingThis early-stage study tests a new drug called FZ-AD005 in 40 people with aggressive brain tumors (high-grade glioma) that have come back or not responded to treatment. The drug is designed to target and kill cancer cells while sparing healthy ones. The main goals are to find the…
Phase: PHASE1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for kids with tough cancers: drug combo trial launches
Disease control Not yet recruitingThis study tests a combination of chemotherapy drugs (liposomal irinotecan, vincristine, and temozolomide) with or without an additional drug (anlotinib) in children aged 3-18 whose solid tumors have returned or not responded to treatment. The goal is to see if this combination c…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug T320 targets tough tumors in early trial
Disease control Not yet recruitingThis early-stage study tests a new drug called T320 in 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive T320 every two wee…
Phase: PHASE1 • Sponsor: Nanolattix Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered t cells take on Hard-to-Treat cancers in new trial
Disease control Not yet recruitingThis early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered macrophages take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental 'Off-the-Shelf' NK cells aim to fight childhood leukemia
Disease control Not yet recruitingThis early-phase trial tests JY509, a universal natural killer (NK) cell therapy, in 18 children with relapsed or refractory B-cell acute lymphoblastic leukemia. The cells are given as a single injection to see if they are safe and can help control the disease. The study uses a d…
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New cell therapy aims to train immune system against hard-to-treat cancers
Disease control Not yet recruitingThis early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…
Phase: NA • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New hope for young brain cancer patients: enzyme therapy targets tumors
Disease control Not yet recruitingThis study tests a drug called ADI-PEG 20, which breaks down an amino acid that some brain tumors need to grow. It is given alongside standard radiation and chemotherapy to children, adolescents, and young adults with newly diagnosed high-grade glioma. The goal is to see if this …
Phase: PHASE1, PHASE2 • Sponsor: Sabine Mueller, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Immune cells engineered to fight brain cancer in kids
Disease control Not yet recruitingThis early-phase study tests the safety of a new cell therapy called B7-H3 CAR T cells for children and young adults whose brain tumors have come back or are growing despite standard treatment. The therapy uses the patient's own immune cells, modified to target a protein (B7-H3) …
Phase: PHASE1 • Sponsor: Robbie Majzner • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug QLS5316 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, a…
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New CAR t cell therapy targets tough childhood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests whether a new cell therapy called B7-H3 CAR T cells is safe and can help children and young adults whose solid tumors have returned or stopped responding to standard treatments. About 40 participants will receive their own immune cells that have been …
Phase: PHASE1 • Sponsor: Robbie Majzner • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Microtransplantation: a new hope for advanced cancer patients?
Disease control Not yet recruitingThis early-stage trial tests a procedure called microtransplantation (MST) combined with chemotherapy in 10 adults with advanced or relapsed solid tumors. The goal is to see if MST can help control the disease and improve recovery of blood cells after chemo. The study focuses on …
Phase: PHASE1 • Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Can a smart thermometer protect kids on chemo from dangerous fevers?
Disease control Not yet recruitingThis study tests whether a remote temperature monitor can help detect fever early in children undergoing chemotherapy who are at risk of a serious infection called febrile neutropenia. About 30 children from families with social or emotional challenges will either use a wearable …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de la Réunion • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Nasal spray could deliver brain tumor treatment directly to Kids' tumors
Disease control Not yet recruitingThis early-phase trial tests a nasal spray called NEO100 (a purified natural compound) in 12 children with certain aggressive brain tumors. The goal is to see if it's safe, find the best dose, and check if the drug reaches the tumor. Participants will receive increasing doses, an…
Phase: PHASE1 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Personalized cell therapy takes on Hard-to-Treat tumors
Disease control Not yet recruitingThis early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of che…
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Supercharged T-Cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a new therapy called TCR-T cells, which are immune cells engineered to recognize and attack cancer cells with specific KRAS mutations (G12V or G12D). The study will enroll 25 adults with advanced solid tumors (like colorectal or lung cancer) who have …
Phase: EARLY_PHASE1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug FXS887 enters first human tests for tough cancers
Disease control Not yet recruitingThis early-stage trial tests a new drug called FXS887 in 14 people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein (ATR) that cancer cells need to repair their DNA. The main goals are to check safety, find the r…
Phase: PHASE1 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cancer drug HX111 enters early human trials
Disease control Not yet recruitingThis study tests a new drug, HX111, in about 70 people with advanced solid tumors or lymphoma that has not responded to other treatments. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-stage trial, so the main focus is on safety and side eff…
Phase: PHASE1, PHASE2 • Sponsor: Hanx Biopharmaceuticals (Wuhan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New combo aims to fix Chemo-Caused low platelets
Disease control Not yet recruitingThis Phase 2 trial tests whether combining two platelet-boosting drugs (hetrombopag and rhTPO) works better than hetrombopag alone for cancer patients with dangerously low platelets from treatment. About 204 adults with solid tumors will be randomly assigned to one of the two gro…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for kids with tough brain cancers: experimental drug trial launches
Disease control Not yet recruitingThis early-stage study tests an experimental drug called gallium maltolate in 15 children whose high-grade glioma or atypical teratoid rhabdoid tumor has returned or not responded to treatment. The main goals are to find safe doses and understand side effects. Everyone receives t…
Phase: PHASE1 • Sponsor: Sarah Rumler • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New pill takes on advanced cancers in early human trial
Disease control Not yet recruitingThis study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…
Phase: PHASE1, PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Off-the-Shelf cell therapy takes aim at tough blood cancers
Disease control Not yet recruitingThis early study tests a new treatment for people with B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses donor immune cells (CAR-T cells) designed to find and attack cancer cells. The main goal is to check if it's safe, with a small…
Phase: PHASE1 • Sponsor: YANRU WANG • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Can a new pill tame immunotherapy's worst side effects and let patients restart treatment?
Disease control Not yet recruitingThis study tests a drug called ivarmacitinib in 72 people with advanced solid tumors who had to stop their cancer immunotherapy because of severe immune-related side effects. The goal is to see if the drug can control those side effects and, if successful, allow patients to safel…
Phase: PHASE2 • Sponsor: Fujian Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for rare cancers: china launches massive drug trial
Disease control Not yet recruitingThis study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…
Phase: PHASE1, PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Could a pill replace IV drips for leukemia patients?
Disease control Not yet recruitingThis phase 3 trial is testing whether an oral (pill) form of arsenic trioxide works as well as the standard IV form for consolidation therapy in people with a low-risk type of acute promyelocytic leukemia (APL). About 120 adults and teens who have already completed initial treatm…
Phase: PHASE3 • Sponsor: SDK Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New pill targets cancer growth pathway in advanced tumors
Disease control Not yet recruitingThis study tests a new drug called TYK-01054 for people with advanced solid tumors that have not responded to standard treatments. The drug is taken as a capsule and works by blocking a protein (TEAD) involved in cancer growth. The trial will check safety, find the best dose, and…
Phase: PHASE1, PHASE2 • Sponsor: TYK Medicines, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New gene therapy trial hopes to tame advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new treatment called KXV01 TCR Lentinvivo in 30 adults with advanced solid tumors that have not responded to standard therapies. The main goal is to check safety and find the right dose. The treatment uses a virus to deliver cancer-fighting genes in…
Phase: PHASE1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New cancer pill enters first human tests
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called ISM5939, taken as a pill, in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study will first test the drug alone, then in combination with chemotherapy (cisplatin or doce…
Phase: PHASE1 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Mushroom-Derived compound joins forces with radiation and immunotherapy to fight advanced cancers
Disease control Not yet recruitingThis phase 2 trial tests a combination of PRaG-1 Cordycepin Tablets (from a fungus), radiation therapy, immune-boosting injections, and immunotherapy drugs in 65 adults with advanced solid tumors who have no standard treatment options. The goal is to see if this mix improves immu…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could cutting vitamin B6 boost cancer immunotherapy?
Disease control Not yet recruitingThis early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New pill hopes to fight multiple cancers when other treatments fail
Disease control Not yet recruitingThis early-stage trial tests an experimental drug called ACC-1898, taken as a daily pill, in adults with advanced solid tumors (like liver, kidney, or stomach cancer) that have not responded to standard treatments. The main goals are to find a safe dose and see how the body handl…
Phase: PHASE1 • Sponsor: AccSalus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for tough cancers: experimental drug TB511 enters human trials
Disease control Not yet recruitingThis early-phase trial tests a new drug called TB511 in people with advanced solid tumors (lung, prostate, colorectal, or liver cancer) that have stopped responding to standard care. The study has two parts: first, finding the safest dose of TB511 alone; second, testing TB511 com…
Phase: PHASE1, PHASE2 • Sponsor: Twinpig Biolab, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New mRNA vaccine takes on advanced cancers in early trial
Disease control Not yet recruitingThis study tests a new mRNA vaccine designed to help the immune system attack cancer cells. The vaccine targets a protein found only in tumors and is given together with an immunotherapy drug (anti-PD-1). About 60 adults with advanced solid tumors that cannot be removed by surger…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New radioactive 'Theranostic' drugs aim to find and treat brain tumors
Disease control Not yet recruitingThis study tests special radioactive drugs that can both find and treat solid tumors that have spread to the brain. Ten adults with advanced breast cancer and active brain metastases will receive a single dose of a diagnostic agent to see if it lights up the brain tumors on a sca…
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New program aims to catch late effects in childhood cancer survivors
Disease control Not yet recruitingThis trial tests a program called ONLOOP that reminds adult survivors of childhood cancer to get important screening tests. These tests can find late effects like heart disease or second cancers early. About 900 survivors in Ontario will be randomly assigned to get the reminders …
Phase: NA • Sponsor: The Hospital for Sick Children • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Kidney shield? drug may protect young cancer patients from chemo harm
Disease control Not yet recruitingThis study tests whether the drug aminophylline can protect the kidneys of children receiving cisplatin chemotherapy. Twenty-four children will be randomly assigned to receive either aminophylline or a placebo alongside their standard chemo hydration. Researchers will measure kid…
Phase: PHASE2, PHASE3 • Sponsor: Mahidol University • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New gene therapy trial hopes to fight Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called KXV01 TCR Lentinvivo for people with advanced solid tumors that have not responded to standard therapies. The main goals are to check safety and find the right dose. About 30 adults aged 18 to 70 will take part, and researchers …
Phase: PHASE1 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug ATB-320 enters first human tests for advanced cancers
Disease control Not yet recruitingThis early-stage study tests a new drug, ATB-320, in 24 adults with solid tumors that have spread or are getting worse despite standard treatments. The main goal is to find a safe dose and check for side effects. Participants must provide tumor samples and have tumors that can be…
Phase: PHASE1 • Sponsor: Autotelicbio • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 in people with advanced solid tumors that have RAS mutations, including pancreatic, lung, and colorectal cancers. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks if the drug shrinks tumors. About …
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Custom immune attack: new gene therapy targets Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial tests a personalized gene therapy called KXV01 TCR Lentinvivo Injection for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a virus to deliver cancer-fighting genes into the patient's own immune cells. The …
Phase: PHASE1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Cancer drug RVU120 gets extended trial for ongoing patients
Disease control Not yet recruitingThis study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…
Phase: PHASE2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug aims to fix Chemo-Induced low platelets
Disease control Not yet recruitingThis study tests a drug called Romiplostim N01 in 106 cancer patients whose platelets drop due to chemo, radiation, or immunotherapy. The goal is to see if it can safely raise platelet counts better than the current standard treatment. Patients will be randomly assigned to receiv…
Phase: NA • Sponsor: Jun wang • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental drug combo aims to make radiation safer for kids with deadly brain tumor
Disease control Not yet recruitingThis phase 3 trial tests whether adding two experimental drugs (Atengenal and Astugenal) to standard radiation affects heart rhythm in children aged 3–21 with newly diagnosed diffuse intrinsic brainstem glioma. The study will enroll 30 participants and monitor heart electrical ac…
Phase: PHASE3 • Sponsor: Burzynski Research Institute • Aim: Disease control
Last updated Jun 26, 2026 19:09 UTC
-
Experimental drug combo aims to fight deadly brainstem glioma
Disease control Not yet recruitingThis phase 3 trial tests whether adding two experimental drugs (Atengenal and Astugenal) to standard radiation therapy helps people aged 3 and older with a newly diagnosed, aggressive brainstem tumor live longer. About 92 participants will be randomly assigned to get either radia…
Phase: PHASE3 • Sponsor: Burzynski Research Institute • Aim: Disease control
Last updated Jun 26, 2026 18:42 UTC
-
New drug combo aims to fight Hard-to-Treat cancers
Disease control Not yet recruitingThis early-phase trial is testing a combination of two experimental drugs, IMM2510 and IMM01, in about 104 people with advanced solid tumors that have already been treated. The goal is to find safe doses and see if the combination can shrink tumors. The study is not yet recruitin…
Phase: PHASE1, PHASE2 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:39 UTC
-
New combo therapy aims to tackle Hard-to-Treat cancers
Disease control Not yet recruitingThis study tests a new drug called CVL006 combined with standard chemotherapy or other targeted drugs in people with advanced solid tumors that have not responded to previous treatments. The trial has two phases: first, to find the safest dose, and second, to see if the combinati…
Phase: PHASE1, PHASE2 • Sponsor: Convalife (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
New hope for cancer patients: drug may fix Radiation-Related low platelets
Disease control Not yet recruitingThis phase 2 trial tests whether romiplostim N01 can safely raise low platelet counts in 60 adults with solid tumors who have had radiotherapy combined with other treatments. The main goal is to see if platelet counts increase by at least 50 billion per liter within two weeks. Th…
Phase: PHASE2 • Sponsor: Zhujiang Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:03 UTC
-
New Dual-Targeted PET scan aims to spot cancers more clearly
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…
Phase: NA • Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 13:06 UTC
-
New 'Smart' PET scan could spot hidden cancers
Diagnosis Not yet recruitingThis study tests a new radioactive tracer called 68Ga-MY for PET scans. It targets a protein (5T4) found on many cancer cells but rarely on healthy cells. About 20 people with lung or breast cancer will get both a standard FDG scan and a 68Ga-MY scan. Researchers will compare the…
Phase: NA • Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Could a simple scan replace biopsies for cancer immunotherapy?
Diagnosis Not yet recruitingThis study tests a new PET imaging agent, 68Ga-cPP-BCH, to detect PD-L1 protein levels in tumors of people with lung cancer, melanoma, or other solid tumors. The goal is to see if this scan can identify who might benefit from anti-PD-1/PD-L1 immunotherapy without needing a tissue…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
New heart tests aim to catch damage early in kids treated for cancer
Diagnosis Not yet recruitingThis study looks at whether advanced heart tests and blood markers can find early signs of heart damage in children who had chemotherapy or chest radiation for cancer. About 100 survivors aged 2 to 25 will undergo special echocardiograms, exercise tests, and wear activity monitor…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Liege • Aim: Diagnosis
Last updated Jun 27, 2026 09:04 UTC
-
New trial aims to slash deadly bloodstream infections from hospital tubes
Prevention Not yet recruitingThis study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…
Phase: NA • Sponsor: The University of Queensland • Aim: Prevention
Last updated Jun 27, 2026 12:33 UTC
-
Light therapy may soothe chemo mouth sores in children
Prevention Not yet recruitingThis study tests if a special light (photobiomodulation) can prevent and treat painful mouth sores caused by chemotherapy in children aged 4-17 with cancer. Half of the 49 participants will get light therapy, and the other half will get a standard gel. The goal is to see if the l…
Phase: NA • Sponsor: Universidad de Guanajuato • Aim: Prevention
Last updated Jun 27, 2026 09:00 UTC
-
Glutamine supplement may shield kids from chemo nerve pain
Prevention Not yet recruitingThis study tests whether the supplement glutamine can prevent nerve damage caused by the chemotherapy drug vincristine in children and teens with cancer. About 70 participants, aged 6 to 18, will take glutamine twice daily for 14 days during their treatment. Researchers will trac…
Phase: PHASE3 • Sponsor: Ain Shams University • Aim: Prevention
Last updated Jun 27, 2026 08:04 UTC
-
Timing your meals might ease cancer treatment side effects
Symptom relief Not yet recruitingThis study tests if eating only within an 8-hour window each day (time-restricted eating) can reduce treatment side effects and improve quality of life for people with solid tumors starting adjuvant therapy after surgery. Fifty adults will be randomly assigned to follow this eati…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Could kids with bone cancer go home sooner after chemo?
Symptom relief Not yet recruitingThis study looks at whether children, teens, and young adults with newly diagnosed osteosarcoma can safely leave the hospital when their methotrexate levels are slightly higher than usual after standard chemotherapy. The goal is to shorten hospital stays without increasing side e…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Mind-Body therapies tested to calm anxiety in childhood cancer survivors
Symptom relief Not yet recruitingThis study looks at whether adding hypnosis or relaxation sessions to standard psychological care can lower anxiety in children, teens, and young adults who have finished treatment for pediatric cancer. About 558 participants aged 7 to 25 who are in remission and have anxiety wil…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Exercise program aims to boost strength in young cancer patients
Symptom relief Not yet recruitingThe BEPPO study is testing whether a structured exercise program can improve physical and mental health in 346 children and teens (ages 3-18) undergoing cancer treatment across 13 German centers. Participants are randomly assigned to either a 6-month exercise program (3-5 session…
Phase: NA • Sponsor: Universität Duisburg-Essen • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Ice chips vs. mouth sores: simple trick may ease chemo side effect
Symptom relief Not yet recruitingThis study tests whether sucking on ice chips during chemotherapy can prevent or reduce the severity of painful mouth sores (oral mucositis) in cancer patients. 102 adults receiving 5-fluorouracil or methotrexate will be randomly assigned to either get ice chips during infusion p…
Phase: NA • Sponsor: University of Health Sciences Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Dance away chemo pain: new study tests fun exercise for nerve damage
Symptom relief Not yet recruitingThis study tests whether a 6-week dance-based exercise program can reduce nerve pain and improve quality of life in cancer patients who have nerve damage from chemotherapy. About 76 adults with solid tumors will either join the dance program or receive usual care. The goal is to …
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
App aims to get teens moving after beating blood cancer
Symptom relief Not yet recruitingThis study tests a mobile app designed to encourage physical activity in adolescents aged 12-18 who have completed treatment for blood cancers like leukemia or lymphoma. Thirty participants will either use the app or receive usual care. The main goal is to see if a larger study i…
Phase: NA • Sponsor: The Hong Kong Polytechnic University • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
New program aims to help young cancer survivors talk with their families
Symptom relief Not yet recruitingThis study tests a new program that helps young Hispanic/Latino adults who survived childhood cancer communicate better with their families and doctors. The program uses a community health worker to guide conversations before and after a clinic visit. The study will enroll 18 sur…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Video prep may ease needle fear in kids with leukemia
Symptom relief Not yet recruitingThis study tests whether showing a short educational video before a subcutaneous injection can reduce anxiety and crying in children aged 3 to 6 with leukemia. Sixty children will be split into three groups: video plus emotional preparation, emotional preparation alone, or standa…
Phase: NA • Sponsor: Ege University • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC
-
Dance therapy from home: a new hope for kids battling cancer
Symptom relief Not yet recruitingThis study tests whether an 8-week online dance therapy program can improve movement skills, quality of life, and daily participation in 30 children aged 6–14 who have or recently finished cancer treatment. The program is done via video calls, making it easy to join from home. Re…
Phase: NA • Sponsor: Akdeniz University • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Music and VR tested to soothe kids with leukaemia during painful mouth care
Symptom relief Not yet recruitingThis study tests whether listening to calming music or using virtual reality can reduce pain, anxiety, and fear in children aged 6-12 with leukaemia who need care for painful mouth sores caused by chemotherapy. Forty-five children will be randomly assigned to a music group, a VR …
Phase: NA • Sponsor: Ege University • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Simple exercises may soothe chemo nerve damage
Symptom relief Not yet recruitingThis study tests whether a 15-minute hand and foot exercise routine can reduce nerve pain caused by Taxane chemotherapy in cancer patients. Fifty-eight adults with mild nerve symptoms will either do the exercises plus standard care or receive standard care alone. Researchers will…
Phase: NA • Sponsor: University of Health Sciences Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Miracle fruit may bring back taste for cancer patients
Symptom relief Not yet recruitingThis pilot study tests whether freeze-dried miracle fruit (MiraBurst) can improve taste changes in people with solid tumors undergoing cancer treatment. About 45 adults will take one mini-square before each meal for 90 days. The goal is to see if this simple supplement can ease a…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:25 UTC
-
New app aims to empower young cancer survivors
Symptom relief Not yet recruitingThis study tests a web app called MyCare eQuoL that helps childhood cancer survivors assess their needs and get personalized support. About 200 survivors aged 16-30 from nine European countries will use the app for six months. The goal is to see if the app helps them feel more in…
Sponsor: Istituto Giannina Gaslini • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Horse power: equicoaching aims to rebuild social lives of young cancer survivors
Symptom relief Not yet recruitingThis study explores whether equicoaching—a type of coaching with horses—can help young adults (ages 15-25) who finished cancer treatment feel more confident and reconnect with others. Ten participants will take part in the program and share their experiences through interviews an…
Phase: NA • Sponsor: Centre Leon Berard • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Can medically tailored meals help kids with cancer and their caregivers?
Symptom relief Not yet recruitingThis study tests a 12-week program that provides medically tailored meals and coaching from a dietitian to children undergoing cancer treatment and their caregivers. The goal is to see if the program is practical and helpful for improving nutrition and reducing caregiver stress. …
Phase: NA • Sponsor: Drexel University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Playtime prescription: new study aims to help young cancer patients thrive
Symptom relief Not yet recruitingThis study looks at whether structured physical activity and play can help preschool children with cancer improve their motor skills and development. About 82 children aged 1-5 will take part in a 9-month program that includes group play at the hospital, parent education, and onl…
Phase: NA • Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Herbal soak may soothe Chemo's painful side effects
Symptom relief Not yet recruitingThis study tests whether a traditional Chinese medicine hand-foot soak can reduce nerve pain and skin reactions caused by chemotherapy. About 300 adults with solid tumors who have these side effects will use the soak. The goal is to see if it improves symptoms and quality of life…
Sponsor: Peking University Third Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Art therapy trial aims to ease anxiety in teens battling cancer
Symptom relief Not yet recruitingThis study tests a 4-week art-based program that combines relaxation exercises with creative activities like emotion-color mapping and gratitude mandalas. The goal is to see if it reduces anxiety, improves emotion regulation, and lessens symptom burden in 60 adolescents aged 10-1…
Phase: NA • Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 08:15 UTC
-
Vision boards give teens with cancer a boost of hope
Symptom relief Not yet recruitingThis study tests a 5-week vision board program designed to increase hope and psychological strength in teenagers who have been undergoing cancer treatment for at least six months. Sixty adolescents aged 12 to 18 will be randomly assigned to either the vision board program or stan…
Phase: NA • Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
AI art therapy aims to ease chemo anxiety in kids
Symptom relief Not yet recruitingThis study tests whether an AI-assisted art therapy program can help children aged 10-18 feel better emotionally and physically during chemotherapy. Over four days, kids create art with AI guidance to reduce anxiety and symptom burden. The trial involves 60 participants and compa…
Phase: NA • Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Teens with cancer test wearable tech to fight fatigue
Symptom relief Not yet recruitingThis study tests whether a wearable activity tracker and guided exercise app can reduce fatigue and improve quality of life in teens aged 13-18 who are undergoing cancer treatment. Half of the 50 participants will follow an 8-week structured exercise program using the wearable, w…
Phase: NA • Sponsor: Istanbul University • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
New app aims to help parents tackle Kids' cancer pain at home
Symptom relief Not yet recruitingThis pilot study tests a smartphone app called PainCaRe, designed to help parents of young children (ages 2-11) with cancer manage their child's pain at home. The app asks parents to report their child's pain daily and gives personalized, evidence-based pain relief tips. The stud…
Phase: NA • Sponsor: The Hospital for Sick Children • Aim: Symptom relief
Last updated Jun 27, 2026 08:04 UTC
-
New nurse program aims to ease cancer survivors' transition home
Symptom relief Not yet recruitingThis study tests a 12-week nurse-led program for childhood cancer survivors aged 13-18 and their parents. The program includes face-to-face and online sessions to help manage symptoms, improve self-care, and connect families with other health professionals. Sixty-eight families w…
Phase: NA • Sponsor: The Hong Kong Polytechnic University • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
Can video calls replace clinic visits for palliative care?
Symptom relief Not yet recruitingThis study tests whether virtual palliative care (via video calls) works as well as standard in-person care for adults with cancer. About 252 participants will be randomly assigned to one of the two approaches. Researchers will measure quality of life, symptom burden, and satisfa…
Phase: NA • Sponsor: Al Al Bayt University, Jordan • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
New app aims to boost mental strength in hospitalized teens with cancer
Symptom relief Not yet recruitingThis study will test a new mobile app called CesiKids, designed by nurses, recovered teens, and parents, to help adolescents aged 12-18 with cancer build psychological resilience while in the hospital. The app uses AI to adapt to each teen's needs and includes activities to stren…
Phase: NA • Sponsor: Eskisehir Osmangazi University • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Food as medicine: new program aims to ease life for families of young cancer survivors
Symptom relief Not yet recruitingThis study tests if a program that delivers healthy food and teaches cooking skills is helpful for parents of children who have finished cancer treatment. The study will include 21 parents of children aged 5-12 who completed cancer therapy within the last five years. Researchers …
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Weekly scans may make proton therapy safer for kids with cancer
Knowledge-focused Not yet recruitingThis study will enroll 100 children with solid tumors or Hodgkin lymphoma who are receiving proton therapy. Researchers will take weekly or bi-weekly CT or MRI scans during treatment to check if the original radiation plan is still accurate. If tumor coverage drops by 5% or radia…
Phase: NA • Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Smartwatches could save young lives in ghana by catching danger signs earlier
Knowledge-focused Not yet recruitingThis study will see if using a Garmin smartwatch to continuously track heart rate, breathing rate, and oxygen levels can help doctors spot early warning signs in hospitalized children in Ghana. About 250 children with traumatic injuries or after appendix surgery will wear the wat…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
DNA testing could make cancer drugs safer for kids
Knowledge-focused Not yet recruitingThis study looks at how a child's genes affect the way their body processes cancer medications. By testing 130 children and young adults (up to age 26) with newly diagnosed cancer, researchers hope to find genetic differences that could help doctors choose safer and more effectiv…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
4D MRI scans could reveal hidden clues about heart disease and cancer
Knowledge-focused Not yet recruitingThis study uses advanced 4D MRI scans to measure blood flow and heart function in adults with heart disease or cancer. Researchers aim to see if these detailed images can help predict how these diseases will progress. The study involves 1,000 participants who are already schedule…
Sponsor: Ulsan University Hospital • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Why do childhood cancer survivors age faster? new study aims to find out
Knowledge-focused Not yet recruitingThis study will examine muscle health in 533 adult survivors of childhood cancer and compare them to people without a cancer history. Using advanced imaging and tests, researchers hope to identify different types of muscle problems. The goal is to better understand why survivors …
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Scientists investigate how immune cells fight leukemia
Knowledge-focused Not yet recruitingThis study will collect blood and bone marrow samples from 55 adults with acute leukemia or myelodysplastic syndrome. Researchers want to understand how natural killer (NK) cells interact with cancer cells over time. The goal is to identify genetic markers and immune patterns tha…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Music may soothe chemo mouth sores in kids
Knowledge-focused Not yet recruitingThis study looks at whether music therapy can reduce painful mouth sores (oral mucositis) in children with cancer. Researchers will interview 50 families online to learn about their experiences with music therapy. The goal is to find patterns that could lead to better, drug-free …
Phase: NA • Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Tracing a cancer Drug's journey through the body
Knowledge-focused Not yet recruitingThis study tracks how the experimental drug AZD1390 moves through and leaves the body after a single dose. It involves about 8 adults with advanced solid tumors who are not currently on active cancer treatment. By using a tiny radioactive label, researchers can measure the drug i…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New program aims to keep young cancer survivors from falling through healthcare cracks
Knowledge-focused Not yet recruitingThis study tests whether a patient navigation program helps young adult survivors of childhood cancer successfully transition from pediatric to adult-focused healthcare. About 190 participants aged 20-29 will be randomly assigned to receive either the navigation program or standa…
Phase: NA • Sponsor: Children's Hospital Los Angeles • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Does breakfast change how chemo works? new study investigates
Knowledge-focused Not yet recruitingThis early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…
Phase: PHASE1 • Sponsor: Health Hope Pharma • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can text messages help parents of kids with cancer stick with treatment?
Knowledge-focused Not yet recruitingThis study compares three ways to teach caregivers about childhood cancer: text messages, tablet modules in the clinic, or standard doctor-led education. Researchers want to see which method helps caregivers learn best and reduces the chance that a family stops treatment early. A…
Phase: NA • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Leukemia drug timing under the microscope: new study aims to improve dosing
Knowledge-focused Not yet recruitingThis study looks at how long the drug calaspargase pegol stays at effective levels in the blood of children and young adults with acute lymphoblastic leukemia or lymphoma. Researchers will measure drug activity and check for links to side effects. The goal is to better understand…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Can a simple quiz spot frailty in older cancer patients?
Knowledge-focused Not yet recruitingThis study checks if a short questionnaire called G8 can correctly identify frailty in people aged 70 and older with solid tumors. Researchers will compare the G8 results with a full geriatric assessment in 150 patients. The goal is to see if the G8 tool works well for Portuguese…
Sponsor: Hospital de Braga • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Scientists hunt for biological clues to Cancer-Related anxiety and depression
Knowledge-focused Not yet recruitingThis study looks for biological markers in tumor tissue and blood that may be linked to anxiety and depression in people with solid tumors. Researchers will combine psychological assessments with lab tests to better understand these emotional struggles. The goal is to improve ear…
Sponsor: The First Affiliated Hospital of Xinxiang Medical College • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
New cancer trial aims to crack the code of who benefits from immunotherapy
Knowledge-focused Not yet recruitingThis study enrolls 275 people with advanced solid tumors to test a new approach: using a rapid, detailed analysis of each patient's tumor and immune system to guide treatment choices. The goal is to improve the success rate of immunotherapy, which currently helps only 20-30% of p…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New study tracks brain health in kids after stem cell transplants
Knowledge-focused Not yet recruitingThis observational study will follow 100 children in Denmark who receive a stem cell transplant for blood cancer or other serious blood disorders. Researchers will test their thinking skills, physical abilities, and daily activity before the transplant and for one year after. The…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Nurse training aims to cut infections in young cancer patients
Knowledge-focused Not yet recruitingThis study tests whether a training program for pediatric oncology nurses improves their knowledge and infection prevention behaviors when caring for central venous catheters (CVCs). Thirty nurses will receive education including a presentation, video, and hands-on practice. Thei…
Phase: NA • Sponsor: Fenerbahce University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Can better staff talk save kids with cancer? new study tests team training
Knowledge-focused Not yet recruitingThis study tests a program to improve how hospital staff communicate when caring for children with cancer in low-resource settings. The program includes training and new protocols for teamwork. Researchers will measure changes in communication quality over six months. Only 8 hosp…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
New study to track recovery in kids with brain tumors
Knowledge-focused Not yet recruitingThis study will follow 30 children under 18 who have surgery for a specific type of brain tumor (midline posterior fossa tumors). The goal is to see how well they recover and what factors affect their recovery and survival. The results may help doctors better predict outcomes and…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Study reveals hidden toll on parents of kids with cancer
Knowledge-focused Not yet recruitingThis study looks at how caring for a child with cancer impacts the caregiver's quality of life and sense of burden. Researchers will survey 95 primary caregivers of children aged 0-18 who are undergoing active cancer treatment. The goal is to understand the relationship between c…
Sponsor: Fatma Beyza Akdeniz • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
New study aims to predict heart side effects in kids treated for cancer
Knowledge-focused Not yet recruitingThis study will check if certain blood markers can predict heart damage in children and teens who had anthracycline chemotherapy for cancer. Researchers will compare blood tests and heart imaging results from 40 survivors and healthy volunteers. The goal is to find early warning …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
VR pain relief for kids: scientists scan brains to see how it works
Knowledge-focused Not yet recruitingThis study will use a special brain scanner to see how virtual reality (VR) affects pain in children aged 6-17 with burns. Four children will have their brain activity measured during burn dressing changes, both with and without VR. The goal is to find brain markers that show whe…
Phase: NA • Sponsor: Nationwide Children's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New registry aims to decode mysterious immune side effects of cancer drugs
Knowledge-focused Not yet recruitingThis study creates a registry of 500 cancer patients receiving immunotherapy to better understand and manage immune-related side effects (irAEs). Researchers will collect data on who gets these side effects, how they present, and what treatments work best. The goal is to improve …
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
New tool to measure Cancer's financial toll tested in turkey
Knowledge-focused Not yet recruitingThis study aims to adapt a questionnaire called PROFFIT, originally developed in Italy, to measure financial toxicity (the financial burden of cancer treatment) in Turkish patients. Researchers will enroll 320 adults with cancer who have received treatment in the last three month…
Sponsor: Akdeniz University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC
-
Gut check: could your microbiome predict fertility after immunotherapy?
Knowledge-focused Not yet recruitingThis observational study looks at how immune checkpoint inhibitors (a type of cancer immunotherapy) affect ovarian function and fertility in women aged 18-38 with solid tumors. Researchers will collect blood and stool samples before and during treatment to measure hormone levels …
Sponsor: West China Second University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Leukemia meds may mess with your thyroid – new study to find out how
Knowledge-focused Not yet recruitingThis study will check how certain leukemia drugs (called tyrosine kinase inhibitors) affect the thyroid gland in people with chronic myeloid leukemia. Researchers will measure thyroid hormone levels in 76 newly diagnosed adults over time. The goal is to learn how often thyroid pr…
Sponsor: Assiut University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
Real-world test of adebrelimab combo for tough cancers
Knowledge-focused Not yet recruitingThis study will observe 300 people with advanced lung or gastrointestinal cancers who receive adebrelimab combined with other treatments. Researchers will track side effects and how well the cancer responds. It is a real-world study, meaning it watches what happens in regular med…
Sponsor: Tianjin First Central Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:13 UTC
-
New blood test aims to predict who will respond to immunotherapy
Knowledge-focused Not yet recruitingThis study will test a new automated blood test that measures how well a patient's T-cells (immune cells) are working. The goal is to see if the test results match how well the cancer responds to standard immunotherapy drugs like anti-PD1 or anti-CTLA4. The study will include 100…
Phase: NA • Sponsor: Centre Leon Berard • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:54 UTC
-
Massive data pool aims to crack childhood Leukemia's toughest cases
Knowledge-focused Not yet recruitingThis study will gather and combine medical and genetic data from 2,000 children with acute myeloid leukemia (AML) across France. The goal is to find hidden patterns that predict which patients are most likely to relapse. By creating a large, shared database, researchers hope to i…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:37 UTC